Trending...
- $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
- Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
- Slick Cash Loan shares credit score tips for borrowers using bad credit loans
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
- IYKYK! Coffee Lab Thriving in Huntington Beach, Blending Elevated Coffee, Matcha, Music, and Community
- Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
- Sacred Surrogacy, CFC, and Egghelpers Launch Women's Retreats
- The Eichelberger Performing Arts Center Donates Theatrical Lights to Delone Catholic High School
- Moravian Academy Becomes First Pennsylvania School to Partner with Global Sustainability Institute
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
- Stipenda Appoints David Epstein as Chief Operating Officer
- Woven Wire Mesh as a Durable Filter Medium for Industrial Filtration Systems
- FondoQuantaX Completes Core Trading Engine Upgrade: Refactoring High-Concurrency Architecture with AI Adaptive Algorithms to Navigate Market Extremes
- As Paris Hilton Reclaims Her Icon Status, "Pretty Pop Star" Reemerges to Battle the Age of AI Music
- Food Journal Magazine Is Shaping the Conversation Around Los Angeles Food in 2026
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
0 Comments
Latest on The PennZone
- One-Click Pro Audio for Streamers: "VoiceSterize" Automates Noise Reduction & Mastering on Mac
- Sole Publishing Announces Essential Parenting Book for Families Navigating the Teen Years
- From Factory Floor to Community Heart: The Rebel Spirit of Wisconsin's Wet Wipe Innovators
- UK Financial Ltd Lists MayaFund (MFUND) ERC-20 Token on CATEX Exchange Ahead of Planned ERC-3643 Upgrade
- Benjamin Ross Group Has Secured Financing for a Company with a Sale Price of $1,050,000
- Denver Apartment Finders Launches Revamped Denver Tech Center Apartment Location Page
- Roblox and Solsten Alliances; a Stronger Balance Sheet and Accelerated Growth Through AI, Gaming, and Strategic Partnerships for Super League: $SLE
- Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
- Power Business Solutions Announces Joint Venture with EIG Global Trust to Deliver Data Center Financial Solutions
- Scoop Social Co. Partners with Fairmont Hotels & Resorts to Elevate Summer Guest Experiences with Italian Inspired Gelato & Beverage Carts
- Buildout Launches Native Email Marketing Feature, Expanding Its End-to-End CRE Platform
- New Saxophone Prize Honors Astronaut Ronald E. McNair, First To Play Sax In Space
- Building a $145M AI-Powered Marine Platform as Listings Surge, Global Expansion Begins, OTH Shares Trade at a Discount: Off The Hook YS (N Y S E: OTH)
- American Disabilities Act Must Protect Against Forced Psychiatric Commitment and Treatment
- 2025 Top Lawyers - ELA Awards by Expert Law Attorneys
- Top Law Firms In 2025 - Expert Law Attorneys
- Best Personal Injury Attorneys Of 2025 - ELA Awards
- Best Personal Injury Law Firms 2025 - ELA Awards
- Baruch Arcade Launches AI-Powered Gaming Platform on Solana, do I smell an airdrop?
- Expert Law Attorneys 2025 Best Attorneys
